ASX - Delayed Quote AUD
Imugene Limited (IMU.AX)
At close: October 25 at 4:10 PM GMT+11
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Operating Expense
145,700.5730
145,700.5730
51,293.2260
50,673.1430
25,666.1490
--
Operating Income
-145,700.5730
-145,700.5730
-51,293.2260
-50,673.1430
-25,666.1490
--
Net Non Operating Interest Income Expense
4,037.2620
4,037.2620
1,852.3490
71.9250
10.5090
--
Other Income Expense
-8,017.2280
-8,017.2280
11,525.9870
12,732.0440
7,200.2770
--
Pretax Income
-149,680.5390
-149,680.5390
-37,914.8900
-37,869.1740
-18,455.3630
--
Net Income Common Stockholders
-149,680.5390
-149,680.5390
-37,914.8900
-37,869.1740
-18,455.3630
--
Basic EPS
-0.02
--
-0.01
-0.01
-0.00
-0.00
Diluted EPS
-0.02
--
-0.01
-0.01
-0.00
-0.00
Basic Average Shares
7,088,807.7040
--
6,317,915.9680
5,637,196.7970
4,663,540.9720
4,074,894.3020
Diluted Average Shares
7,088,807.7040
--
6,317,915.9680
5,637,196.7970
4,663,540.9720
4,074,894.3020
Net Income from Continuing & Discontinued Operation
-149,680.5390
-149,680.5390
-37,914.8900
-37,869.1740
-18,455.3630
--
Normalized Income
-138,418.0220
-138,418.0220
-37,912.4810
-37,764.3250
-18,455.3630
--
Interest Income
4,515.6230
4,515.6230
1,879.8020
192.2490
126.5650
--
Interest Expense
--
--
--
106.7440
111.0320
5.0290
Net Interest Income
4,037.2620
4,037.2620
1,852.3490
71.9250
10.5090
--
EBIT
-145,700.5730
-145,700.5730
-51,293.2260
-37,762.4300
-18,344.3310
--
EBITDA
-142,411.8430
-142,411.8430
-51,102.9060
-37,559.0730
-18,240.1280
--
Reconciled Depreciation
3,288.7300
3,288.7300
190.3200
203.3570
104.2030
--
Net Income from Continuing Operation Net Minority Interest
-149,680.5390
-149,680.5390
-37,914.8900
-37,869.1740
-18,455.3630
--
Total Unusual Items Excluding Goodwill
-11,262.5170
-11,262.5170
-2.4090
-104.8490
--
--
Total Unusual Items
-11,262.5170
-11,262.5170
-2.4090
-104.8490
--
--
Normalized EBITDA
-131,149.3260
-131,149.3260
-51,100.4970
-37,454.2240
-18,240.1280
--
6/30/2020 - 12/30/1993
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RAD.AX Radiopharm Theranostics Limited
0.0260
-3.70%
IMM.AX Immutep Limited
0.2950
0.00%
NYR.AX Nyrada Inc.
0.1400
0.00%
CUV.AX Clinuvel Pharmaceuticals Limited
14.50
+2.40%
CHM.AX Chimeric Therapeutics Limited
0.0100
+11.11%
DXB.AX Dimerix Limited
0.4200
+2.44%
NEU.AX Neuren Pharmaceuticals Limited
12.47
+0.16%
TLX.AX Telix Pharmaceuticals Limited
20.90
-2.61%
IXC.AX Invex Therapeutics Ltd
0.0770
-6.10%
NOVA.MU Novo Nordisk A/S
106.00
-0.93%